Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva And Celltrion Gain Arthritis Advantage On Rituximab

Truxima Biosimilar Now Available In Rheumatoid Arthritis Indication In US

Executive Summary

Teva and Celltrion’s Truxima rituximab biosimilar is now available with a rheumatoid arthritis indication in the US, the firms have revealed, giving it a potential advantage over Pfizer’s Ruxience version.

You may also be interested in...



Amgen Rivals Teva With Rituximab Approved For RA

Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.

Henlius Wins Chinese Approval For Rituximab RA Indication

Henlius says it can now pursue a “differentiated strategy” for its HLX01 rituximab biosimilar in China, after winning approval for a key rheumatoid arthritis indication from the NMPA.

Teva Blends Branded And Generic Mindsets To Boost Biosimilars

Teva is “uniquely qualified” to succeed with biosimilars thanks to the dual branded and generic mindsets that it can bring to the table, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the second part of an exclusive interview.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel